Rectal cancer. Clinical practice guidelines in oncology.

Paul F. Engstrom*, A. B. Benson, Leonard Saltz, Comprehensive Cancer Network National Comprehensive Cancer Network

*Corresponding author for this work

Research output: Contribution to journalArticle

15 Scopus citations

Abstract

The NCCN Rectal Cancer Guidelines panel believes that a multidisciplinary approach is necessary for treating patients with colorectal cancer. Patients with T1 or T2 lesions that are node negative by endorectal ultrasound and who meet carefully defined criteria can be managed with a transanal excision. Abdominal peritoneal resection or low anterior resection with total mesorectal excision is appropriate for all other rectal lesions. Either preoperative chemoradiation or postoperative chemoradiotherapy is standard for patients with suspected or proven serosal invasion (pT3) or regional node involvement. Patients with recurrent localized disease should be considered for resection with or without radiotherapy. Chemotherapy regimens using irinotecan or oxaliplatin should be considered for patients with distant metastasis. The panel endorses the concept that treating patients in a clinical trial has priority over standard or accepted therapy.

Original languageEnglish (US)
Pages (from-to)54-63
Number of pages10
JournalJournal of the National Comprehensive Cancer Network : JNCCN
Volume1
Issue number1
StatePublished - Jan 1 2003

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Rectal cancer. Clinical practice guidelines in oncology.'. Together they form a unique fingerprint.

  • Cite this

    Engstrom, P. F., Benson, A. B., Saltz, L., & National Comprehensive Cancer Network, C. C. N. (2003). Rectal cancer. Clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network : JNCCN, 1(1), 54-63.